During the past decade, CHU Poitiers - Pôle régional de Cancérologie conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 2 clinical trials were completed, i.e. on average, 11.8% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 2 clinical trials were completed. i.e. 18.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Poitiers - Pôle régional de Cancérologie" #1 sponsor was "Intergroupe Francophone du Myelome" with 4 trials, followed by "ARCAGY/ GINECO GROUP" with 3 trials sponsored, "Loxo Oncology, Inc." with 3 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "UNICANCER" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Poitiers - Pôle régional de Cancérologie" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Sanofi" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "CHU Poitiers - Pôle régional de Cancérologie" are "Multiple Myeloma" (4 trials), "Ovarian Cancer" (3 trials), "Breast Cancer" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials) and "Small Lymphocytic Lymphoma" (2 trials). Many other conditions were trialed in "CHU Poitiers - Pôle régional de Cancérologie" in a lesser frequency.

Most popular intervention types in "CHU Poitiers - Pôle régional de Cancérologie" are "Drug" (17 trials), "Procedure" (2 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Isatuximab" (2 trials), "Pirtobrutinib" (2 trials), "Placebo" (2 trials), "Rituximab" (2 trials) and "Trastuzumab Emtansine" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHU Poitiers - Pôle régional de Cancérologie" are 15 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CHU Poitiers - Pôle régional de Cancérologie". undefined are not yet recruiting, 9 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in CHU Poitiers - Pôle régional de Cancérologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHU Poitiers - Pôle régional de Cancérologie, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".